
Intellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema
Intellia Therapeutics Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema — Highlights Durable Benefit and Safety Intellia Therapeutics, a leading clinical-stage genome-editing biotechnology company, today presented updated…












